Initial data from the IGNYTE clinical trial demonstrate that the combination of the oncolytic virus RP1 and nivolumab (PD-1 immune…
en_news
The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment…
The analysis of homologous recombination DNA repair in primary breast and ovarian tumours in patients with pathogenic germline variants in…
In this chapter of Cancer 360 the journalist Adam Martín talks to 8 professionals from VHIO who work in different…
After the success achieved last year, VHIO has once again organized, on April 20, its Open Day, with the aim…
Laura Soucek, an ICREA Research Professor, Director of VHIO’s Experimental Therapeutics Program, and Head of our Models of Cancer Therapies…
On April 3, the VII National Medicine Awards organized by the magazine El Suplemento were presented. Dr. Josep Tabernero, director…
Results of the multi-center iPROMET study identify whole-body magnetic resonance imaging as a biomarker of response in prostate cancer patients…
Developed by VHIO’s Radiomics Group in close collaboration with researchers of the Neuro-Radiology Unit at the Bellvitge University Hospital (HUB),…
The predictability of response criteria remains controversial in drug development. Numerous reviews and meta-analyses continue to question the reliability of…
